peptide hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-13. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
=== Colonial and Revolutionary eras === True Asian tea (Camellia Sinensis) was first brought to North America by Dutch traders in the 17th century. In the Dutch colony of New Amsterdam, now known as New York, tea was served with the best silver strainers, the finest porcelain cups and pots, and wooden tea caddies. Regular shipments of tea to the American colonies began in the 1720s. Legally, American colonists were only supposed to buy British tea, but in reality, smuggling was widespread, and Dutch, French, and other teas were widely available. Asian tea soon became a very popular drink in the American colonies, and tea parties were common among all classes. The first tea vendors in Boston were Benjamin Harris and Daniel Vernon, who received licenses to sell tea in 1690. In Salem, Massachusetts, tea leaves were boiled to create a bitter brew, then served as a vegetable side dish with butter. By the time of the American Revolution, tea was drunk everywhere from the backwoods to the cities. The view of tea in American culture began to shift when the British government introduced the Townshend Acts in 1767. Tea was taxed as part of these laws which made it less affordable for the colonial population. However, cheaper tea was still smuggled into America. Later in 1773 the Tea Act was put into place which allowed the East India Company (EIC) to gain a monopoly on tea sales in America by being able to sell tea at prices that were cheaper than both the colonial tea importers and smugglers.
== Commercial availability == The first telephone freeze alarms reached the consumer market in the late 1980s, notably the Sensaphone 400 (also marketed as “CottageSitter”). During the 2010s, internet-connected monitors such as the Temperature@lert WiFi350 and the Elertus Smart Sensor popularised cloud dashboards. Cellular multi-sensor units now dominate the remote-property segment because they remain operational through power and internet outages, albeit with a required data subscription. Entry-level local indicators cost under US$100, whereas cellular systems with cloud services typically retail for US$150–300 plus monthly fees.
The classic click reaction is the copper-catalyzed reaction of an azide with an alkyne to form a 5-membered C2N3 ring. This reaction is the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC). The first triazole synthesis, from diethyl acetylenedicarboxylate and phenyl azide, was reported by Arthur Michael in 1893. Later, in the middle of the twentieth century, this family of 1,3-dipolar cycloadditions took on Rolf Huisgen's name after his studies of their reaction kinetics and conditions.
Beginning in 1928, Stalin's five-year plans for the national economy of the Soviet Union achieved the rapid industrialisation (coal, iron and steel, electricity and petroleum, among others) and the collectivisation of agriculture. It achieved 23.6% of collectivisation within two years (1930) and 98.0% of collectivisation within thirteen years (1941). As the revolutionary vanguard, the communist party organised Russian society to realise rapid industrialisation programs as defence against Western interference with socialism in Bolshevik Russia. The five-year plans were prepared in the 1920s whilst the Bolshevik government fought the internal Russian Civil War (1917–1922) and repelled the external Allied intervention to the Russian Civil War (1918–1925). Vast industrialisation was initiated mostly based with a focus on heavy industry. The Cultural revolution in the Soviet Union focused on restructuring culture and society.
Sources: en.wikipedia.org
==== Assisted death in Canada ==== A lethal dose of propofol is used for medical assistance in dying in Canada to induce deep coma and death quickly, but rocuronium is always given as a paralytic, ensuring death, even when the patient has died as a result of an initial propofol overdose.
If, in the very intense electric field in the neighbourhood of the cathode, the molecules of the gas are dissociated and are split up, not into the ordinary chemical atoms, but into these primordial atoms, which we shall for brevity call corpuscles; and if these corpuscles are charged with electricity and projected from the cathode by the electric field, they would behave exactly like the cathode rays. Thomson imagined the atom as being made up of these corpuscles orbiting in a sea of positive charge; this was his plum pudding model. This model was later proved incorrect when his student Ernest Rutherford showed that the positive charge is concentrated in the nucleus of the atom.
=== Subsidiaries === 2GO Express, Inc. – Provides land, air, and sea transportation including courier services, general cargo, sea cargo services, and last-mile delivery for e-commerce. It operates a nationwide network of retail outlets and partner agents and partners with FedEx for international express services. 2GO Logistics, Inc. – Provides transportation, warehousing, cross-docking, trucking, domestic freight, and inventory management solutions nationwide. Kerry Logistics (Phils.), Inc. (KLPI) – A joint venture with Kerry Logistics Network Limited of Hong Kong, offering domestic and international freight forwarding, warehousing, distribution, customs brokerage, project logistics, and handling of dangerous goods. 2GO Land Transport, Inc. – Provides cargo hauling and forwarding via trucks, container vans, and closed vans. 2GO Retail – Offers domestic parcel delivery, FedEx international services, and 2GO Travel ticket sales through retail outlets and partner agents. Special Container and Value Added Services, Inc. (SCVASI) – Provides cold chain and liquid bulk transport solutions, including temperature-controlled vans and ISO tanks for FCL and LCL shipments, as well as project logistics for industries such as infrastructure, power, telecommunications, mining, and property. 2GO operates passenger and freight services connecting major ports across the Philippines, linking Luzon, the Visayas, and Mindanao.
Sources: en.wikipedia.org
=== Pure Leaf === Pure Leaf is an iced tea brand distributed primarily in the Americas by the PepsiCo-Lipton joint venture. Unlike Lipton Iced Tea and Brisk, which use a freeze-dried instant tea powder, Pure Leaf is brewed in liquid. The brand is sold in square bottles made of recyclable PET plastic.
=== 1982–1994 === The company established its presence in the US in 1982 via a joint venture with Squibb Corporation and Canada in 1984. In 1985, the company introduced the first insulin pen device called Novopen. In 1989, Novo Industri (Novo Terapeutisk Laboratorium) and Nordisk Gentofte (Nordisk Insulinlaboratorium) merged to become Novo Nordisk, the world's largest producer of insulin with headquarters in Bagsværd, Greater Copenhagen. In 1991, Novo Nordisk Engineering (now NNE) demerged after working as in-house consultants at Novo for years, to provide standard engineering services (end-to-end engineering) to pharma manufacturing companies. In 1994, Novo's existing information technology units was spun out as NNIT. The company was converted into a wholly owned aktieselskab in 2004. In March 2015, NNIT was floated on the Nasdaq Nordic.
Actin filament disassembly The immobilization by interpenetration of actin filaments results from two distinct ABP families. The gelsolin protein family is believed to be the most efficient in the disruption of actin filaments and is considered a "strong severing protein". These proteins respond to an increase in Ca2+ and cap the "barbed end" of the recently severed F-actin. The increased level of Ca2+ may also destabilize the actin-filament network by interfering with the binding of crosslinking proteins. The ADF/Cofilin protein family also serves to severe actin-filament networks through the weak severing of actin networks. This form of weak severing does not tightly cap the "barbed ends" but does allow for the disassociation of actin monomers and thus the disassembly of F-actin. Monomer sequestration that prevents spontaneous nucleation Exists as the turnover point in the actin remodeling cycle. The proteins thymosin and profilin prevent the spontaneous nucleation of new actin trimers. The absence or inhibition of these proteins results in the cell's ability to commence the actin remodeling cycle and produce elongated F-actin.
== Current state of the industry == A tablet counter has become a standard in more than 30,000 sites in 35 countries (as of 2010) (including many non-pharmacy sites, such as manufacturing facilities that use a counting machine as a check for small items). During the 1990s through 2012, numerous new pharmacy automation products came to market. During this timeframe, counting technologies, robotics, workflow management software, and interactive voice recognition (IVR) systems for retail (both chain and independent), outpatient, government, and closed-door pharmacies (mail order and central fill) were all introduced. Additionally, the concept of scalability - of migrating from an entry-level product to the next level of automation (e.g., counting technology to robotics) - was introduced and subsequently launched a new product line in 1997. Pharmacists are transitioning to automation. As the industry evolves and customer expectations grow, automation is emerging as necessity rather than luxury. Especially for independent pharmacies, automation becomes a means of keeping up with the competition of large chain pharmacies.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.